Cocrystal Pharma to Participate in the H.C. Wainwright Global Investment Conference
05 9월 2023 - 9:00PM
Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the
“Company”), a clinical-stage biopharmaceutical company dedicated to
developing novel small molecule antiviral therapeutics, announces
that management will participate in the H.C. Wainwright 25th Annual
Global Investment Conference being held September 11-13, 2023. A
webcast of the Cocrystal presentation will be available on the IR
Calendar section of the Company’s website beginning Monday,
September 11 at 7:00 a.m. Eastern time.
Management is available throughout the
conference for in-person and virtual one-on-one meetings.
Institutional investors and industry professionals can register to
attend the conference virtually or in-person at the Lotte New York
Palace Hotel.
About Cocrystal Pharma,
Inc.
Cocrystal Pharma, Inc. is a clinical-stage
biotechnology company discovering and developing novel antiviral
therapeutics that target the replication process of influenza
viruses, coronaviruses (including SARS-CoV-2 and noroviruses) and
hepatitis C viruses. Cocrystal employs unique structure-based
technologies and Nobel Prize-winning expertise to create first- and
best-in-class antiviral drugs. For further information about
Cocrystal, please visit www.cocrystalpharma.com.
Investor Contact:LHA Investor
RelationsJody Cain310-691-7100jcain@lhai.com
Media Contact:JQA PartnersJules
Abraham917-885-7378Jabraham@jqapartners.com
# # #
Cocrystal Pharma (NASDAQ:COCP)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Cocrystal Pharma (NASDAQ:COCP)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024